Jubilant Biosys signs pact with BioLeap

Bangalore: Jubilant Biosys Ltd, the Bangalore-based research subsidiary of Jubilant Organosys Ltd, on Tuesday announced a drug discovery partnership with US company BioLeap, LLC. They will form a highly competitive pre-clinical drug development platform by integrating BioLeap's computational fragment-based drug design platform with Jubilant's expertise in chemistry, biology and crystallography, a release here said. They will offer services from lead identification and optimisation to investigational new drug candidate selection for multiple therapeutic areas, the release said quoting Mr Sri Mosur, CEO and President, Jubilant Biosys, and Mr Gerald Evans, BioLeap's Chief Business Officer. BioLeap's in silico technology can quickly predict binding information to help drug designers create novel molecules and improve existing molecules without the limitations of library screening. It reduces the time and cost of traditional screening methods, the company said